Metabolic-associated fatty liver disease (MAFLD) in coeliac disease.

Abstract

Coeliac disease (CD) is considered a high-risk condition for developing non-alcoholic fatty liver disease (NAFLD) and other related metabolic disorders, particularly after commencing gluten-free diet (GFD). Recently, a new concept of metabolic-associated fatty liver disease (MAFLD) has been proposed to overcome the limitations of NAFLD definition. This study aimed at exploring the prevalence of NAFLD and MAFLD in CD patients at the time of CD diagnosis and after 2years of GFD. Furthermore, we evaluated the role of PNPLA3 rs738409 in the development of NAFLD and MAFLD in the same population. We retrospectively enrolled all newly diagnosed CD patients who underwent clinical, laboratory and ultrasonography investigations both at diagnosis and after 2years of follow-up. Moreover, a PNPLA3 rs738409 genotyping assay was performed. Of 221 newly diagnosed CD patients, 65 (29.4%) presented NAFLD at CD diagnosis, while 32 (14.5%) met the criteria for MAFLD (k=0.57). There were no significant differences between NAFLD and MAFLD, except for the higher rate of insulin resistance (IR) of MAFLD patients (75% vs 33.8%, P<.001). At 2years of follow-up, 46.6% of patients developed NAFLD while 32.6% had MAFLD (k=0.71). MAFLD subjects had higher transaminases (P=.03), LDL-cholesterol (P=.04), BMI and waist circumference and higher IR than NAFLD patients. MAFLD patients showed higher non-invasive liver fibrosis scores than NAFLD subjects (APRI=1.43±0.56 vs 0.91±0.62, P<.001; NFS=-1.72±1.31 vs -2.18±1.41, P=.03; FIB-4=1.27±0.77 vs 1.04±0.74, P=.04). About PNPLA3 polymorphisms, at 2years follow-up, NAFLD subjects presented a higher rate of heterozygosis (40.8%) and homozygosis (18.4%) polymorphisms than non-NAFLD (26.3% and 7.6%, respectively, P=.03 and 0.02), while no correlation between PNPLA3 polymorphisms and MAFLD was seen. The new MAFLD definition better reflects the metabolic alterations following GFD in CD population. This new classification could be able to identify patients at higher risk of worse metabolic outcome, who need a close multidisciplinary approach for their multisystemic disease.